In June, the Food and Drug Administration will decide whether to grant full approval to Biogen and Eisai’s anti-amyloid Alzheimer’s drug Leqembi (generic name…
UPDATE: 3 March 2024, 8:21 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
According to drugmaker Eli Lilly, the FDA has rejected the company’s application for the FDA’s “Accelerated Approval” designation for experimental Alzheimer’s drug donanemab. The…
Update: As of July 6, 2023, the drug has full, traditional FDA approval. Today, the Food and Drug Administration approved Leqembi (generic name lecanemab), a…
The approval of the controversial anti-amyloid drug Aduhelm last year marked a major milestone for Alzheimer’s research — it became the first new drug…
Much anticipated Phase 3 data for Alzheimer’s drug lecanemab was presented at CTAD in 2022, showing the drug is as safe as the placebo…
Update 27 January, 2023: In January 2023, lecanemab was granted accelerated approval by the FDA and made available to patients under the brand name…
Most Alzheimer’s treatments on the market today help manage symptoms, like memory loss — but they don’t get at the root cause. Roche hoped their…
There were more than 140 experimental Alzheimer’s drugs in clinical trials as of the start of 2022. On the one hand, this number inspires…
UPDATE: 3 March 2024, 8:35 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Vaccines are considered one of the greatest innovations in medical history. Immunizations help train the body’s immune system to recognize and respond to a…
UPDATE: 3 March 2024, 8:37 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
UPDATE: 3 March 2024, 8:39 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
The lack of effective treatments for Alzheimer’s have spurred scientists to rethink the dominant approach to tackling the disease: the amyloid hypothesis. This hypothesis…
UPDATE: 3 March 2024, 8:27 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…